OverviewSuggest Edit

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.

TypePublic
Founded1992
HQPlanegg, DE
Websitemorphosys.com
Employee Ratings3.4

Latest Updates

Employees (est.) (May 2021)615(-3%)
Job Openings40
Share Price (May 2021)€80(+5%)
Cybersecurity ratingBMore

Key People/Management at MorphoSys

Jean-Paul Kress

Jean-Paul Kress

Chief Executive Officer
Malte Peters

Malte Peters

Chief Research and Development Officer
Charlotte Lohmann

Charlotte Lohmann

SVP General Counsel
Sung Lee

Sung Lee

Chief Financial Officer
Marc Cluzel

Marc Cluzel

Chairman
Barbara Krebs-Pohl

Barbara Krebs-Pohl

SVP, Head of Global BD&L and Alliance Management
Show more

MorphoSys Office Locations

MorphoSys has offices in Planegg and Boston
Planegg, DE (HQ)
Semmelweisstraße 7
Boston, MA, US
470 Atlantic Ave #1401
Show all (2)

MorphoSys Financials and Metrics

MorphoSys Revenue

Market capitalization (3-May-2021)

2.7b

Closing stock price (3-May-2021)

80.0
MorphoSys's current market capitalization is €2.7 b.
Show all financial metrics

MorphoSys Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

MorphoSys Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

MorphoSys Online and Social Media Presence

Embed Graph

MorphoSys News and Updates

Chief scientist quits at Germany's Morphosys ahead of product launch

Morphosys' chief scientific officer will quit after 17 years with the group, the latest change at the top of the German biotech firm as it gears up for its first product launch.

I-Mab Biopharma and MorphoSys Announce IND Clearance to Initiate Clinical Trials of TJ202/MOR202 for the Treatment of Multiple Myeloma in Mainland China

SHANGHAI, Oct. 14, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases and German...

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

I-Mab Biopharma and MorphoSys Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

SHANGHAI, March 19, 2019 /PRNewswire/ -- I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and autoimmune diseases, and German biopharma company MorphoSys AG (FSE: MOR; Prime...

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

Mechelen, Belgium and Planegg/Munich, Germany; 13 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR1…

Galapagos en MorphoSys kondigen de start aan van een Fase 1 subcutane overbruggingsstudie met MOR106

Mechelen, België en Planegg / München, Duitsland; 13 september 2018; 22.01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) en MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) hebben vandaag de start aangekondigd van een Fase 1 overbruggingsstudie voor het onderzoeken van een …
Show more

MorphoSys Blogs

Corporate Governance Inhalt NEU EN

Statement on Corporate Governance In the Statement on Corporate Governance under Section 289f HGB and the Group Statement on Corporate Governance pursuant to Section 315d, the Management Board and the Supervisory Board present information on the most essential components of our corporat…

Alliance Text EN

The negotiation and management of partnerships has been MorphoSys’ foundation and will continue to play an important role also in our future to maximize value creation and serving patients worldwide. The teams are closely integrated within Global BD&L to ensure a smooth transition fr…

Alliance Text DE

The negotiation and management of partnerships has been MorphoSys’ foundation and will continue to play an important role also in our future to maximize value creation and serving patients worldwide. The teams are closely integrated within Global BD&L to ensure a smooth transition fr…

Business Development & Licensing Text EN

The MorphoSys Business Development & Licensing team approaches collaborations and licensing deals with the aim of addressing the needs and aligning the contributions of both partners. The ultimate goal for our award-winning BD&L team is to define the combined strengths of such pa…

Business Development & Licensing Text DE

The MorphoSys Business Development & Licensing team approaches collaborations and licensing deals with the aim of addressing the needs and aligning the contributions of both partners. The ultimate goal for our award-winning BD&L team is to define the combined strengths of such pa…

Globales BD&L und Alliance Management

Globales BD&L und Alliance Management EN
Show more

MorphoSys Frequently Asked Questions

  • When was MorphoSys founded?

    MorphoSys was founded in 1992.

  • Who are MorphoSys key executives?

    MorphoSys's key executives are Jean-Paul Kress, Malte Peters and Charlotte Lohmann.

  • How many employees does MorphoSys have?

    MorphoSys has 615 employees.

  • Who are MorphoSys competitors?

    Competitors of MorphoSys include Microcoat Biotechnologie, Prometheus Biosciences and Biosan Laboratories.

  • Where is MorphoSys headquarters?

    MorphoSys headquarters is located at Semmelweisstraße 7, Planegg.

  • Where are MorphoSys offices?

    MorphoSys has offices in Planegg and Boston.

  • How many offices does MorphoSys have?

    MorphoSys has 2 offices.